MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.
Patent Owner
Stats
- 28 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Sep 20, 2016 most recent publication
Details
- 28 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 1,431 Total Citation Count
- Aug 19, 1981 Earliest Filing
- 79 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9447166 Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptorsMar 31, 14Sep 20, 16[A61K, C07H, A01K, C07K]
8435947 Endothelial nitric oxide synthase antagonists and uses thereof for inhibiting oxygen toxicityMay 09, 11May 07, 13[A61K]
8309534 Compositions comprising a GPR109 ligand for treating disorders of the digestive tract and/or cancerMay 15, 08Nov 13, 12[A61K, A01N]
8211864 Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptorsJan 26, 06Jul 03, 12[A61K, C07H, C12N]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0152,413 Composition and Method for In Vivo and In Vitro Attenuation of Gene Expression Using Double Stranded RNAAbandonedSep 05, 14Jun 04, 15[C12N]
2012/0288,472 REGULATION OF T CELL-MEDIATED IMMUNITY BY TRYPTOPHANAbandonedMay 21, 12Nov 15, 12[A61K, A61P]
2012/0141,998 ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCEAbandonedFeb 15, 12Jun 07, 12[C12Q, G01N]
2012/0142,750 INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLSAbandonedNov 30, 11Jun 07, 12[A61K, A61P]
2011/0305,713 METHODS AND COMPOSITIONS TO ENHANCE VACCINE EFFICACY BY REPROGRAMMING REGULATORY T CELLSAbandonedApr 13, 11Dec 15, 11[A61K, C12N, A61P]
2011/0135,572 COMPOSITIONS AND METHODS FOR DIAGNOSING LATE-ONSET ALZHEIMER'S DISEASEAbandonedMay 28, 10Jun 09, 11[A61K, C12Q, C40B]
2011/0135,672 HLA-G COMPOSITIONS AND METHODS OF USE THEREOFAbandonedMay 27, 10Jun 09, 11[A61K, B82Y, C12N, A61P, C07K, B32B]
2011/0123,590 Selective Expansion of Regulatory T CellsAbandonedMay 17, 10May 26, 11[A61K, C12N, C12M]
2011/0124,678 TREATMENT WITH ALPHA 7-SELECTIVE LIGANDSAbandonedAug 01, 08May 26, 11[A61K, C07D, A61P]
2011/0124,720 COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISORDERSAbandonedJan 05, 11May 26, 11[A61K, C07D, A61P]
2011/0047,631 HEAT SHOCK PROTEIN DEFICIENCIES AS MODEL SYSTEMS FOR BRAIN PATHOLOGY AND CANCERAbandonedJan 08, 10Feb 24, 11[A61K, C12Q, C12N, G01N, A01K, A61P]
2010/0324,064 NOVEL ANALOGS OF CHOLINE FOR NEUROPROTECTION AND COGNITIVE ENHANCEMENT IN NEURODEGENERATIVE DISORDERSAbandonedJul 22, 10Dec 23, 10[A61K, C07D, C07C, A61P]
2010/0297,160 High Molecular Weight Amyloid Beta As a Carrier for the Oral Delivery of Vaccine AntigensAbandonedMay 14, 10Nov 25, 10[A61K, C12N, A61P]
2010/0287,627 Transgenic Zebrafish Models for Neurodegenerative DiseasesAbandonedDec 23, 09Nov 11, 10[A61K, A61P]
2010/0278,907 Immunogenic Compositions Containing Ceramide and Methods of Use ThereofAbandonedMay 12, 10Nov 04, 10[A61K, A61P]
2010/0266,588 Breast Cancer Susceptibility Gene GT198 and Uses ThereofAbandonedApr 20, 10Oct 21, 10[A61K, C12Q, A61P]
2010/0267,042 Antigen-Presenting Cell Populations And Their Use As Reagents For Enhancing Or Reducing Immune ToleranceAbandonedApr 01, 10Oct 21, 10[C12Q, G01N]
2010/0212,038 TRANSGENIC FISH WITH TISSUE-SPECIFIC EXPRESSIONAbandonedJan 16, 09Aug 19, 10[C12Q, C12N, A01K]
2010/0111,943 COMPOSITIONS AND METHODS FOR INHIBITING CANCER METASTASISAbandonedMar 24, 08May 06, 10[A61K, C07H, C12N, C07K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.